• +1-646-491-9876
    • +91-20-67278686

    Search

    Gallbladder Cancer-Pipeline Review H1 2017

    Gallbladder Cancer-Pipeline Review H1 2017

    • Report Code ID: RW0001834387
    • Category Pharmaceuticals
    • No. of Pages 118
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Gallbladder Cancer - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H1 2017, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.

    Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts. Treatment includes surgery, chemotherapy and radiation therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Gallbladder Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 10, 4 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

    Gallbladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Gallbladder Cancer (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Gallbladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Gallbladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Gallbladder Cancer (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Gallbladder Cancer (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Gallbladder Cancer (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Gallbladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Gallbladder Cancer - Overview
    Gallbladder Cancer - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Gallbladder Cancer - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Gallbladder Cancer - Companies Involved in Therapeutics Development
    Advenchen Laboratories LLC
    Array BioPharma Inc
    Aslan Pharmaceuticals Pte Ltd
    Bayer AG
    BeiGene Ltd
    Eli Lilly and Company
    Halozyme Therapeutics Inc
    Hutchison China MediTech Ltd
    Leap Therapeutics Inc
    Merrimack Pharmaceuticals Inc
    Novartis AG
    NuCana BioMed Ltd
    Threshold Pharmaceuticals Inc
    VasGene Therapeutics Inc
    Gallbladder Cancer - Drug Profiles
    apatinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BGBA-317 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    binimetinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    copanlisib hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DKN-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    evofosfamide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HMPL-012 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    irinotecan hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    merestinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NUC-1031 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PEGPH-20 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ramucirumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    trametinib dimethyl sulfoxide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    varlitinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vas-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gallbladder Cancer - Dormant Projects
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Gallbladder Cancer, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Gallbladder Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
    Gallbladder Cancer - Pipeline by Array BioPharma Inc, H1 2017
    Gallbladder Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2017
    Gallbladder Cancer - Pipeline by Bayer AG, H1 2017
    Gallbladder Cancer - Pipeline by BeiGene Ltd, H1 2017
    Gallbladder Cancer - Pipeline by Eli Lilly and Company, H1 2017
    Gallbladder Cancer - Pipeline by Halozyme Therapeutics Inc, H1 2017
    Gallbladder Cancer - Pipeline by Hutchison China MediTech Ltd, H1 2017
    Gallbladder Cancer - Pipeline by Leap Therapeutics Inc, H1 2017
    Gallbladder Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
    Gallbladder Cancer - Pipeline by Novartis AG, H1 2017
    Gallbladder Cancer - Pipeline by NuCana BioMed Ltd, H1 2017
    Gallbladder Cancer - Pipeline by Threshold Pharmaceuticals Inc, H1 2017
    Gallbladder Cancer - Pipeline by VasGene Therapeutics Inc, H1 2017
    Gallbladder Cancer - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Gallbladder Cancer, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Advenchen Laboratories LLC
    Array BioPharma Inc
    Aslan Pharmaceuticals Pte Ltd
    Bayer AG
    BeiGene Ltd
    Eli Lilly and Company
    Halozyme Therapeutics Inc
    Hutchison China MediTech Ltd
    Leap Therapeutics Inc
    Merrimack Pharmaceuticals Inc
    Novartis AG
    NuCana BioMed Ltd
    Threshold Pharmaceuticals Inc
    VasGene Therapeutics Inc

    Request for Sample

    Report Url https://www.reportsweb.com//gallbladder-cancer-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//gallbladder-cancer-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//gallbladder-cancer-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments